Tau Imaging in the 4-Repeat-Tauopathies Progressive Supranuclear Palsy and Corticobasal Syndrome: A 11C-Pyridinyl-Butadienyl-Benzothiazole 3 PET Pilot Study.

Background And Objectives: To evaluate tau PET using C-pyridinyl-butadienyl-benzothiazole 3 (C-PBB3) in the 4-repeat (4R)-tauopathies progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS).

Methods: Retrospective analysis of C-PBB3 PET in 2, 7, and 2 patients with CBS, PSP, and Alzheimer dementia (AD), respectively. Normalized C-PBB3 uptake in clusters with significant hypometabolism on F-FDG-PET and corresponding atlas-based volumes of interest was compared between diagnostic groups.

The low-energy β(-) and electron emitter (161)Tb as an alternative to (177)Lu for targeted radionuclide therapy.

Introduction: The low-energy β(-) emitter (161)Tb is very similar to (177)Lu with respect to half-life, beta energy and chemical properties. However, (161)Tb also emits a significant amount of conversion and Auger electrons. Greater therapeutic effect can therefore be expected in comparison to (177)Lu.